NCT06746545View on ClinicalTrials.gov

A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

February 1, 2027

Conditions

Colorectal Cancer

Interventions

DRUG

Fruquintinib+S-1

Fruquintinib: 5 mg, oral, once daily，2w/1w；Q3W S-1：40-60 mg (dosed according to body surface area), oral，2w/1w；Q3W

All Listed Sponsors

lead

Fujian Cancer Hospital

OTHER_GOV